Myriad maintained at buy by Merrill Lynch

Myriad Genetics Inc. was maintained by Merrill Lynch analyst David Munno at a buy rating with $24 price target after the company reported that Flurizan improved cognitive function in mild Alzheimer's patients in an open-label follow-on of its phase 2 study. The data suggests that Flurizan may be the first drug for Alzheimer's with disease-modifying properties. Shares of the Salt Lake City molecular and diagnostic-product development company were down 33 cents, or 1.75%, at $18.48 on volume of 288,453 shares versus the three-month running average of 402,635 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.